Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-747-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130.96 million
Profitability
Miscellaneous
Employees507
OptionableOptionable
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) posted its earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, topping the consensus estimate of ($2.65) by $0.47. The biopharmaceutical company earned $47 million during the quarter, compared to analysts' expectations of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The firm's revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.89) earnings per share. View Intercept Pharmaceuticals' Earnings History.
When is Intercept Pharmaceuticals' next earnings date?
What price target have analysts set for ICPT?
17 analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their predictions range from $68.00 to $244.00. On average, they expect Intercept Pharmaceuticals' share price to reach $157.50 in the next year. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.
What is the consensus analysts' recommendation for Intercept Pharmaceuticals?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC. Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. While we are pleased with the approval of Ocaliva, the company’s dependence on a single product for growth has its risks. Any negative news related to Ocaliva would adversely impact Intercept and its growth prospects. The lack of other candidates in the pipeline is concerning. Nevertheless, the company is looking to expand the drug’s label in the promising NASH and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Shares have outperformed the industry in the last six months." (2/15/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $170 12-month price target. We think Elafibranor Ph2 PBC data from Genfit (GNFT.PA, Not covered) looks competitive among Ph2 assets but we do not view today’s update as a near or mid-term threat to ICPT’s OCA. Elafibranor Ph2 looks broadly similar to recently updated Sedalapar data (for 52-week analysis) from Cymabay (CBAY, OW E. Merle) which is not surprising as both are PPAR agonists, but detailed full data could be helpful in comparing the efficacy and safety profiles of these assets. We think pivotal PBC trial enrollment will take time before either asset would pose a commercial threat to OCA in PBC. We remain focused on REGENERATE readout in NASH for ICPT in 1H 2019." (12/6/2018)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
Headlines about ICPT stock have trended somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intercept Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Mark E. Pruzanski, President, Chief Executive Officer & Director
- Jerome B. Durso, Chief Operating Officer
- Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer
- David A. Shapiro, Chief Medical Officer
- Christian Weyer, Executive Vice President-Research & Development
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Trust Advisors LP (3.31%), BB Biotech AG (1.94%), Two Sigma Investments LP (1.05%), Eagle Asset Management Inc. (0.96%), Northern Trust Corp (0.90%) and Geode Capital Management LLC (0.88%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim, Sandip Kapadia and SPA Genextra. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which institutional investors are selling Intercept Pharmaceuticals stock?
ICPT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Elk Creek Partners LLC, Biondo Investment Advisors LLC, South Dakota Investment Council, Pinnacle Associates Ltd., Millennium Management LLC, MetLife Investment Advisors LLC and Virtus ETF Advisers LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski and SPA Genextra. View Insider Buying and Selling for Intercept Pharmaceuticals.
Which institutional investors are buying Intercept Pharmaceuticals stock?
ICPT stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Two Sigma Investments LP, Two Sigma Advisers LP, BB Biotech AG, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., Geode Capital Management LLC and Tekla Capital Management LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $110.82.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $3.29 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.
What is Intercept Pharmaceuticals' official website?
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
